Merit Medical Systems, Inc. (MMSI)
NASDAQ: MMSI · Real-Time Price · USD
83.02
-1.52 (-1.80%)
At close: Jul 18, 2025, 4:00 PM
82.90
-0.12 (-0.14%)
After-hours: Jul 18, 2025, 6:37 PM EDT
Merit Medical Systems Revenue
Merit Medical Systems had revenue of $355.35M in the quarter ending March 31, 2025, with 9.84% growth. This brings the company's revenue in the last twelve months to $1.39B, up 8.19% year-over-year. In the year 2024, Merit Medical Systems had annual revenue of $1.36B with 7.89% growth.
Revenue (ttm)
$1.39B
Revenue Growth
+8.19%
P/S Ratio
3.50
Revenue / Employee
$187,616
Employees
7,400
Market Cap
4.91B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.36B | 99.15M | 7.89% |
Dec 31, 2023 | 1.26B | 106.39M | 9.24% |
Dec 31, 2022 | 1.15B | 76.23M | 7.09% |
Dec 31, 2021 | 1.07B | 110.88M | 11.50% |
Dec 31, 2020 | 963.88M | -30.98M | -3.11% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
MMSI News
- 12 days ago - Merit Medical Names Martha Aronson as New President and Chief Executive Officer - GlobeNewsWire
- 16 days ago - Merit Medical Systems To Announce Second Quarter 2025 Results On July 30, 2025 - GlobeNewsWire
- 5 weeks ago - The Market Is Vulnerable. 6 ‘Defensive' Stocks to Buy Now. - Barrons
- 2 months ago - Merit Medical Acquires Biolife Delaware, L.L.C. - GlobeNewsWire
- 2 months ago - Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis - GlobeNewsWire
- 2 months ago - Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial - GlobeNewsWire
- 3 months ago - Merit Medical Systems, Inc. (MMSI) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Merit Medical Launches the Ventrax™ Delivery System - GlobeNewsWire